Avanir's Reformulated Zenvia Succeeds In Confirmatory Phase III
This article was originally published in Pharmaceutical Approvals Monthly
After battling back from a crippling FDA "approvable" letter for Zenvia, its investigational treatment for the sudden and unpredictable emotional outbursts that can accompany neurologic diseases, Avanir is buoyantly predicting a 2010 launch based on positive top-line data from the Phase III confirmatory study it conducted at the agency’s behest.
You may also be interested in...
Private investments in public equity help firms reach inflection points.
Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.
Confirmatory Phase III trial for Zenvia in involuntary emotional expression disorder set to launch later this year.